Back to company

Neo Biopharm ApS: Financial statements 2025

CVR: 42875708

Neo Biopharm ApS (CVR 42875708) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -357,308 and a net result of DKK -271,403 compared with DKK 157,190 the year before. Equity amounted to DKK 1,994,496. The solvency ratio was 100%.

Gross Profit
-357,308 kr.
Profit/Loss
-271,403 kr.
Equity
1,994,496 kr.
Total Assets
1,994,496 kr.

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2025--357 t.-271 t.2 mio.-
2024-206 t.157 t.2.3 mio.-
2023-528 t.244 t.2.1 mio.-

Official annual report

View the official annual report directly on the page with a Pro subscription.

Find more companies like Neo Biopharm ApS

Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.

Try the lead list generator

Events in 2025

Neo Biopharm ApS: The 2024 annual report is outMar 11, 2025

Neo Biopharm ApS has published its annual report for 2024. Gross profit came to DKK 206,139, and the net result was DKK 157,190.

About Neo Biopharm ApS

Neo Biopharm ApS is a Danish company of the type Anpartsselskab based in Hellerup, founded in 2021. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Jakob Juul Rasmussen. The company is owned by Maryam Badri. In 2025, the company reported a gross profit of DKK -357,308 and a net result of DKK -271,403 compared with DKK 157,190 the year before. Equity amounted to DKK 1,994,496.

Other financial years